Zacks Analyst Interview Highlights: I-Flow, Hologic and TriZetto

Business Wire,  June 6, 2008  

Tags: Hologic Inc., Nasdaq Stock Market Inc.

• E-mail
• Print
• Link

CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Tom Park, who discusses I-Flow (Nasdaq: IFLO), Hologic (Nasdaq: HOLX) and TriZetto (Nasdaq: TZIX).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=2678.

Have you issued any reports discussing quarterly earnings recently?

I recently published a report on I-Flow (Nasdaq: IFLO), which manufactures and sells a line of compact, portable infusion pumps, catheters, and pain kits that administer medication directly to the wound site. The company reported Q1 EPS that beat our estimate by $0.01 on revenue that was below our forecast.

Have any companies in your coverage posted a notable positive surprise as of late?

Hologic (Nasdaq: HOLX), a leading developer, manufacturer, and supplier of diagnostic and medical imaging systems primarily dedicated to serving the healthcare needs of women, reported Q2 EPS that beat our estimate on revenue that significantly exceeded our forecast. However, management lowered its FY08 revenue guidance but reiterated its FY08 EPS guidance.

HOLX completed the acquisition of Cytyc in October 2007. The acquisition is expected to drive revenue and earnings growth significantly higher over the near term and allow the company to continue to grow revenue 20% and EPS 20%+ over the long-term.

What other newsworthy items can you relay for us today?

TriZetto (Nasdaq: TZIX) announced in April that it agreed to be acquired and taken private by funds advised by Apax Partners. Our target price is equal to the cash offer price of $22.00 per share. The company offers proprietary enterprise administration software, enterprise cost and quality of care software, specialized component software, outsourced business services, and consulting services to payers such as health plans and benefits administrators.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks Profit from the Pros e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2679.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4581.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning